Mercury Biopharmaceutical (ROCO:6932) Beginning Cash Position: NT$67.32 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6932 Mercury Biopharmaceutical Corp ROCO:6932
25 GF Score
Price NT$5.49
GF Value NT$36.00
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Mercury Biopharmaceutical Beginning Cash Position?

Mercury Biopharmaceutical ROCO:6932 -8.50% 25 Beginning Cash Position is NT$67.32 Mil as of Dec. 2025. GuruFocus rates ROCO:6932 with a GF Score™ of 25/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 1 warning sign investors should review.

Mercury Biopharmaceutical's Beginning Cash Position for the quarter that ended in Dec. 2025 was NT$67.32 Mil.

Mercury Biopharmaceutical's quarterly Beginning Cash Position declined from Dec. 2024 (NT$166.09 Mil) to Jun. 2025 (NT$68.01 Mil) and declined from Jun. 2025 (NT$68.01 Mil) to Dec. 2025 (NT$67.32 Mil).

Mercury Biopharmaceutical's annual Beginning Cash Position increased from Dec. 2023 (NT$31.94 Mil) to Dec. 2024 (NT$44.29 Mil) and increased from Dec. 2024 (NT$44.29 Mil) to Dec. 2025 (NT$68.01 Mil).

Mercury Biopharmaceutical Beginning Cash Position Related Terms

Mercury Biopharmaceutical Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Mercury Biopharmaceutical's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mercury Biopharmaceutical Beginning Cash Position Chart

Mercury Biopharmaceutical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 0.09 2.56 31.94 44.29 68.01

Mercury Biopharmaceutical Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.84 44.29 166.09 68.01 67.32
ROCO:6932
25GF Score
Mercury Biopharmaceutical Corp ROCO:6932
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mercury Biopharmaceutical Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$67.32 Mil mean?
Mercury Biopharmaceutical (ROCO:6932) has a Beginning Cash Position of NT$67.32 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Mercury Biopharmaceutical and its competitors.
Is Mercury Biopharmaceutical's Beginning Cash Position too high?
Mercury Biopharmaceutical's current Beginning Cash Position is NT$67.32 Mil. Overall, Mercury Biopharmaceutical has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Beginning Cash Position compare to ZTS?
Mercury Biopharmaceutical's Beginning Cash Position of NT$67.32 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Mercury Biopharmaceutical and its competitors. Mercury Biopharmaceutical's current Beginning Cash Position is NT$67.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.49 — trading 84.8% below its estimated fair value. The current Beginning Cash Position is NT$67.32 Mil. Mercury Biopharmaceutical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Beginning Cash Position is NT$67.32 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?

Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued. The current stock price of NT$5.49 is trading 84.8% below its estimated GF Value™ of NT$36.00. GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:6932:

  • Beginning Cash Position: NT$67.32 Mil
  • GF Value™: NT$36.00 vs. price of NT$5.49 (84.8% below fair value)
  • GF Score™: 25/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mercury Biopharmaceutical Business Description

Address No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
25GF Score

Get the complete analysis for ROCO:6932

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$5.49
Price
NT$36.00
GF Value